Background: There have been limited evidences regarding optimal treatment options for in-stent restenosis (ISR). We performed a Bayesian network meta-analysis comparing the efficacy and safety of drug-eluting balloon (DEB), drug-eluting stent (DES), or plain old balloon angioplasty (POBA) for treatment of ISR. Methods: Randomized controlled trials (RCTs) comparing DEB, DES, or POBA for treatment of ISR developed after PCI with bare-metal stent (BMS) or drug-eluting stent (DES) were included to this network meta-analysis. The primary outcome was target lesion revascularization (TLR) after treatment of ISR. The secondary outcomes were myocardial infarction (MI), all-cause mortality, MACE, or binary restenosis at follow-up angiography. The pairwise posterior median OR with 95% CrI in Bayesian meta-analysis was the effect measure.
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Park-Krankenhaus Leipzig, Leipzig, Germany, 2 Medical University Hospital Graz, Graz, Austria, 3 Universitäts-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen, Germany, 4 A.Z. Sint-Blasius, Dendermonde, Belgium, 5 Imelda Ziekenhuis, Bonheiden, Belgium, 6 Charité Berlin, Vascular Center Berlin, Ev. Hospital Königin Elisabeth Herzberge, Berlin, Germany, 7 coreLab Bad Krozingen GmbH, Heart Center Freiburg -Bad Krozingen, Bad Krozingen, Germany, 8 Medical University Graz, Graz, Austria Background: Drug-releasing balloons have shown promising results in femoropopliteal disease; however, adequate evidence demonstrating improved outcomes in infrapopliteal arteries is currently lacking. BIOLUX P-II assesses the safety and performance of the novel BIOTRONIK Passeo-18 Lux Paclitaxel-releasing balloon compared to the uncoated BIOTRONIK Passeo-18 balloon (POBA) in the treatment of infrapopliteal lesions. Methods: BIOLUX P-II is a prospective, international, multicenter, first-in-human, randomized, controlled trial with follow-ups at 30 days, 6 and 12 months. Subjects with single or sequential, de novo or restenotic lesions in the infrapopliteal arteries (!30 mm) were included in the study. A maximum of two different vessels could be treated. The safety primary endpoint was Major Adverse Events (MAE) at 30 days (adjudicated by an independent Clinical Events Committee). The performance primary endpoint was Target Lesion Primary Patency at 6 months by Quantitative Vascular Angiography (assessed by an independent core laboratory, coreLab Bad Krozingen, Germany). Secondary endpoints included freedom from TLR and change in ABI and Rutherford Class. Clinicaltrials.gov: NCT01867736. Results: Seventy-two subjects, 79.2% men, mean age 71.3AE9.7 years, were randomized 1:1 at six European sites. At baseline, subjects presented with hypertension (86.1%), hyperlipidemia (68.1%), diabetes (66.7%) and critical limb ischemia (77.8%). At 30 days, MAE was 0.0% for the DRB vs. 8.3% for POBA, p¼0.239. At 6 months, target lesion primary patency showed a trend in favor of the DRB of 84.3% vs. 75.9% for POBA, p¼0.330 and major amputations were 3.3% for DRB vs. 5.7% for POBA, p¼0.655. Clinical improvement at 6 months, reflected by improvement in Rutherford class was 59% in favor of DRB vs. 47% for POBA, with 0% of DRB subjects worsening vs. 6% POBA, p¼0.326. Clinical improvement of Rutherford 5 subjects was significant for the DRB group (p¼0.002) compared to POBA (p¼0.058). Conclusions: The Passeo-18 Lux DRB, as compared to POBA, is associated with favourable functional and clinical outcomes and results in significant clinical improvement of Rutherford 5 subjects in the treatment of infrapopliteal lesions.
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Paclitaxel-coated balloon angioplasty for drug-eluting stent restenosis: insight from randomized controlled trials Background: Drug-eluting stents (DES) significantly reduce the occurrence of restenosis and the subsequent need for repeat revascularization. Nevertheless, the incidence of DES restenosis remains high due to the continuous increase in DES implantation. Paclitaxel-coated balloon (PCB) angioplasty is superior to plain old balloon angioplasty (POBA) and noninferior to paclitaxel-eluting stent (PES) implantation for bare-metal stent restenosis. Whether the use of PCB angioplasty is also effective in DES restenosis remained contraversial. Thus, We performed a meta-analysis to assess the safety and efficacy of PCB for the treatment of DES restenosis. Methods: Trials were identified through a literature search from January 2005 through April 2014. All randomized controlled trials were eligible for inclusion if they compared PCB with a control treatment (POBA or DES) in patients with DES restenosis. Main endpoints of interest were major adverse cardiac events (MACE), target lesion revascularisation (TLR), binary in-segment restenosis, myocardial infarction (MI) and mortality. A random-effects model was used to calculate the pooled relative risks (RR) with 95% CIs. Results: Five studies and a total of 864 patients were included in this analysis. Follow-up duration ranged from 6 to 12 months. Most endpoints were significantly reduced for PCB compared with the control groups. For MACE, the relative risk RR was 0.49 (0.28 to 0.85), p ¼ 0.012; for TLR, it was 0.50 (0.25 to 0.98), p ¼ 0.044; for angiographic in-segment restenosis, it was 0.41 (0.23 to 0.72), p ¼ 0.002. There was a lower mortality for DEB (RR 0.29 [0.11 to 0.80]; p ¼ 0.017). The incidence of MI was numerically lower, but the differences were not statistically significant (RR 0.76 [0.30 to 1.89]; p ¼ 0.549). Conclusions: In-stent restenosis remains an important issue even in the DES era, and PCB angioplasty is a promising option for the treatment of DES restenosis. It reduces the risk for MACE compared with POBA or implantation of a DES.
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Coronary Lumen Eccentricity is Associated with Amount of Drug Adhesion after Treatment with Drug Coated Balloon Tatsuya Saigusa 1 , Taiji Miyake 2 , Yoshiaki Kawase 2 , Hitoshi Matsuo 3 , Takahiko Suzuki 4 1 Gifu heart center, Gifu, Gifu, 2 Gifu Heart Center, Gifu, Gifu, 3 Gifu Heart Center, Gifu, Japan, 4 Toyohashi Heart Center, Toyohashi, Japan Background: Drug coated balloon (DCB) had efficacy of in-stent restenosis according to previous study. The areas of drug adhesion were not visible with angiography, but optical frequency domain imaging (OFDI) could show them as high intensity spots. The extent of drug adhesion was not always circumferential. The aim of study was to investigate the association between lumen eccentricities and drug adhesion after DCB inflation. Methods: Patients with in-stent coronary artery restenosis were enrolled. OFDI was performed at baseline, after pre dilatation and after DCB inflation. Pre dilatation with usual balloon was performed followed by DCB treatment. Lumen eccentricity was indicated by difference between maximum and minimum lumen diameter. The ratio of drug adhesion area was represented by angle of the bright spot from light source. Results: 12 patients with restenosis lesion were analyzed in this study. Men were 10 (83.3 %), age was 68.7 AE 5.529 years old. Left descending artery was 7 (58.3%), left circumflex artery was 2 (16.7%) and right coronary artery was 3 (25.0%). The restenosis stent was 1 bare metal stent (8.3%), 11 drug eluting stent (91.7%). The difference of maximum and minimum lumen diameter just before DCB treatment was inversely associated with drug adhesion (r¼-0.295, p¼0.004). Lower lumen diameter difference group had more drug adhesion than higher group (p¼0.002). Conclusions: Our study showed lumen eccentricity was associated with amount of drug adhesion. It was ideal to be more concentric coronary lumen before DCB inflation. Importance of pre dilatation was highlighted in our study. www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5 :00 PM-7:00 PM JACC Vol 64/11/Suppl B j September 13-17, 2014 j TCT Abstracts/Drug-Eluting Balloons and Local Drug Delivery B79
